(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum
-
![(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum structure](https://file.echemi.com/fileManage/upload/canonicalSmiles/20220812/0529fdcba6c34d03abdd3eab0e033518.png "(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum")
(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum
structure -
-
CAS No:
63121-00-6
-
Formula:
C8H14N2O4Pt
-
Chemical Name:
(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum
-
Synonyms:
Platinum,[rel-(1R,2R)-1,2-cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]-,(SP-4-2)-;Platinum,(1,2-cyclohexanediamine-N,N′)[ethanedioato(2-)-O,O′]-,[SP-4-2-(trans)]-;Platinum,[rel-(1R,2R)-1,2-cyclohexanediamine-κN,κN′][ethanedioato(2-)-κO1,κO2]-,(SP-4-2)-;1,2-Cyclohexanediamine,platinum complex,trans-;(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum;NSC 271670;ACT 078
- Categories:
-
CAS No:
(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum Basic Attributes
397.29
397.060150
(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum Use and Manufacturing
In 1930, the oxidised compound Oxophenarsine,
containing an As＝O unit, was identified as the active ingredient and was later marketed under the trade
name Mapharsen. Mapharsen was used until the 1940s when it was replaced by Penicillin. Mapharsen was
actually synthesised in Ehrlich’s laboratory as compound number 5, but it was believed to be too toxic for
any clinical application .
Generally, the use of arsenic-based drugs has ceased, especially as a result of the development of Penicillin.
Nevertheless, Melarsoprol and an arsenic-based drug closely related to Atoxyl are licensed to treat sleeping
sickness. Oxaliplatin (cis-[oxalato] trans-1,2-diaminocyclohexane platinum(II)), for example, marketed under the
trade name Eloxatin, is considered as a third-generation platinum-based anticancer drug. Its structure
differs from previously synthesised platinum compounds by the configuration of its amino substituents. Its
platinum centre is coordinated by two chelating ligands, namely an oxalate ligand and a so-called DACH
(1,2-diaminocyclohexane) ligand. In comparison to cisplatin, the two chlorine leaving groups are replaced
by an oxalato leaving group. The simple amino groups are replaced by the DACH ligand, which is the
nonleaving group.
The clinical use of oxaliplatin was approved by the European Union in 1999 and by the FDA in 2002. It
is most effective in combination with 5-fluorouracil and leucovorin (5-FU/LV) in the treatment of metastatic
carcinomas of the colon or rectum. Oxaliplatin induces less side effects than cisplatin; for example, it is
less nephrotoxic and ototoxic and leads to less myelosuppression. Unfortunately, treatment with oxaliplatin
can lead to nerve damage, which may not be reversible in the case of chronic exposure of the patient to the
drug. Oxaliplatin is usually administered intravenously as infusion over a period of 2–6 h in doses similar to
cisplatin. The neurotoxic side effects are dose-limiting .
Recommended Suppliers of (SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum
-
![China]()
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
![China]()
CN
5 YRS
Business licensed Certified factoryManufactory Supplier of Custom Synthetic Chemicals,Biological Stains,Pharmaceutical Intermediates,Cosmetic Grade Chemicals,Enzyme,Nucleosides,Indicators,Speciality Chemicals,Biological Chemicals,Enzyme Substrates -
![China]()
CN
3 YRS
Business licensedTrader Supplier of api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals,CATALYST AND AUXILIARY,FLAVORS AND FRAGRANCES,Chemical Pesticides,ADDITIVE -
![China]()
CN
2 YRS
Business licensedTrader Supplier of API,Antibiotics,Anti cancer categoryInquiryUnit Price: $50 /MT EXWCAS No.: 63121-00-6Grade: Analytical ReagentContent: 99%
Latest News on (SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum
Learn More Other Chemicals
-
[3,4-diacetyloxy-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)oxolan-2-yl]methyl acetate
10302-78-0
-
Atomoxetine Related Compound C (10 mg) (N-methyl-3-phenyl-3-(p-tolyloxy)propan-1-amine hydrochloride)
873310-31-7
-
(3S)-4-Chloro-1,3-butanediol
139013-68-6
-
5-chloro-N-(4-nitrophenyl)pentanamide Formula
1039914-85-6
-
6-AMino-5-azacytidine Formula
105331-00-8
-
Amoxicillin Related Compound D (50 mg) ((4S)-2-{[(R)-2-amino-2-(4-hydroxyphenyl)acetamido](carboxy)methyl}-5,5-dimethylthiazolidine-4-carboxylic acid, monosodium salt) Formula
68728-47-2
-
4-AMINO-6-METHYL-1,3,5-TRIAZIN-2-OL Structure
16352-06-0
-
Littorine Structure
21956-47-8
-
What is 10βH-Guai-11(13)-en-12-oic acid,3α,4:10,14-diepoxy-2β,5,6α,8β-tetrahydroxy-,12,6-lactone,8-(2-methylcrotonate),(Z)-
20071-54-9
-
What is 2-(R)-[1-(S)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy]-3-(S)-fluorophenylmorpholine
170729-79-0
(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum
SDSRequest for Quotation